Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.
暂无分享,去创建一个
D. Selley | M. Banks | S. Negus | W. Dewey | Yan Zhang | E. Townsend | Rolando E Mendez | Mengchu Li | D. L. Stevens | Michelle Arriaga | Nadejda A Blajkevch | David L. Stevens
[1] R. Tallarida,et al. Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966 , 2022, Frontiers in Pharmacology.
[2] M. Hajizadeh,et al. Effect of Methadone Maintenance on Expression of BDNF and CREB Genes in Brain VTA of Male Morphine Treated Rats. , 2021, Central nervous system agents in medicinal chemistry.
[3] F. Bihel,et al. Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. , 2021, RSC medicinal chemistry.
[4] M. Bouvier,et al. Illuminating the complexity of GPCR pathway selectivity - advances in biosensor development. , 2021, Current opinion in structural biology.
[5] G. Collins,et al. Impact of Morphine Dependence and Withdrawal on the Reinforcing Effectiveness of Fentanyl, Cocaine, and Methamphetamine in Rats , 2021, Frontiers in Pharmacology.
[6] M. Banks,et al. A drug-vs-food “choice” self-administration procedure in rats to investigate pharmacological and environmental mechanisms of substance use disorders , 2021, Journal of Neuroscience Methods.
[7] Boshi Huang,et al. Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. , 2021, Bioorganic chemistry.
[8] R. Uprety,et al. Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal , 2021, Cellular and Molecular Neurobiology.
[9] K. Tan,et al. Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation. , 2021, Life sciences.
[10] J. Miller,et al. The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain , 2020, Neuropharmacology.
[11] C. Hartrick,et al. Dual-Acting Peripherally Restricted Delta/Kappa Opioid (CAV1001) Produces Antinociception in Animal Models of Sub-Acute and Chronic Pain , 2020, Journal of pain research.
[12] Yan Zhang,et al. Stereoselective syntheses of 3-dehydroxynaltrexamines and N-methyl-3-dehydroxynaltrexamines. , 2020, Tetrahedron letters.
[13] F. Hsu,et al. Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. , 2020, British journal of anaesthesia.
[14] J. V. Aldrich,et al. Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine‐seeking behaviour , 2020, British journal of pharmacology.
[15] S. Foster,et al. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics , 2020, Neuropharmacology.
[16] S. Schulz,et al. Morphine‐induced respiratory depression is independent of β‐arrestin2 signalling , 2020, British journal of pharmacology.
[17] Bing Yu,et al. Recent Advances in The Rational Drug Design Based on Multi-target Ligands. , 2020, Current medicinal chemistry.
[18] Joshua S. Beckmann,et al. Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats. , 2019, Drug and alcohol dependence.
[19] B. Avery,et al. Investigation of the Adrenergic and Opioid Binding affinities, Metabolic Stability, Plasma Protein Binding Properties and Functional Effects of Selected Indole-based Kratom Alkaloids. , 2019, Journal of medicinal chemistry.
[20] W. Dewey,et al. Fentanyl depression of respiration: comparison with heroin and morphine , 2019, bioRxiv.
[21] K. Berg,et al. Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons , 2019, Neuropharmacology.
[22] Karl T. Schmidt,et al. Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior , 2019, Neuropsychopharmacology.
[23] R. V. van Rijn,et al. A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists , 2019, Front. Pharmacol..
[24] S. B. Caine,et al. Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats , 2019, Neuropsychopharmacology.
[25] S. Schulz,et al. Targeting multiple opioid receptors – improved analgesics with reduced side effects? , 2018, British journal of pharmacology.
[26] Ryan T. Strachan,et al. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor , 2018, Cell.
[27] N. Ozaki,et al. Pharmacokinetics of Morphine in Rats with Adjuvant-induced Arthritis. , 2017, In vivo.
[28] Shelley R. Edwards,et al. Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats , 2017, Psychopharmacology.
[29] Dong-Sheng Cao,et al. ADME Properties Evaluation in Drug Discovery: Prediction of Caco-2 Cell Permeability Using a Combination of NSGA-II and Boosting , 2016, J. Chem. Inf. Model..
[30] D. Kell,et al. Distributed under Creative Commons Cc-by 4.0 the Apparent Permeabilities of Caco-2 Cells to Marketed Drugs: Magnitude, and Independence from Both Biophysical Properties and Endogenite Similarities , 2022 .
[31] G. Pasternak,et al. Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior. , 2015, ACS chemical neuroscience.
[32] N. Imamachi,et al. Effects of Intrathecal &kgr;-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception in Mice , 2015, Regional Anesthesia & Pain Medicine.
[33] G. Mikus,et al. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. , 2014, British journal of anaesthesia.
[34] S. Hirono,et al. Design, synthesis, and structure-activity relationship of novel opioid κ receptor selective agonists: α-iminoamide derivatives with an azabicyclo[2.2.2]octene skeleton. , 2014, Bioorganic & medicinal chemistry letters.
[35] A. Kourounakis,et al. Multi-target drug design approaches for multifactorial diseases: from neurodegenerative to cardiovascular applications. , 2014, Current medicinal chemistry.
[36] K. Schiene,et al. Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[37] B. Kieffer,et al. Knockout subtraction autoradiography: a novel ex vivo method to detect heteromers finds sparse KOP receptor/DOP receptor heterodimerization in the brain. , 2014, European journal of pharmacology.
[38] J. Deruiter,et al. Synthesis and antinociceptive properties of N-phenyl-N-(1-(2-(thiophen-2-yl)ethyl)azepane-4-yl)propionamide in the mouse tail-flick and hot-plate tests. , 2014, Bioorganic & medicinal chemistry letters.
[39] James P. Cain,et al. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. , 2013, Life sciences.
[40] G. Pasternak,et al. Novel 6β-acylaminomorphinans with analgesic activity. , 2013, European journal of medicinal chemistry.
[41] Suzanne Skolnik,et al. Permeability diagnosis model in drug discovery: a diagnostic tool to identify the most influencing properties for gastrointestinal permeability. , 2013, Current topics in medicinal chemistry.
[42] L. Benet,et al. Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements , 2013, The AAPS Journal.
[43] S. Hirono,et al. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 3: synthesis of decahydro(iminoethano)phenanthrene derivatives with an oxygen functionality at the 3-position and their pharmacologies. , 2012, Bioorganic & medicinal chemistry letters.
[44] H. Nagase,et al. Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies. , 2012, Bioorganic & medicinal chemistry letters.
[45] N. Yamaotsu,et al. Essential structure of opioid κ receptor agonist nalfurafine for binding to κ receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies. , 2012, Chemical & pharmaceutical bulletin.
[46] G. Loudos,et al. Molecular nanomedicine towards cancer: ¹¹¹In-labeled nanoparticles. , 2012, Journal of pharmaceutical sciences.
[47] S. Hirono,et al. Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology. Part 2: Propellane derivatives with an amide side chain. , 2012, Bioorganic & medicinal chemistry letters.
[48] Donna A Volpe,et al. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.
[49] V. Hruby,et al. Development of potent μ and δ opioid agonists with high lipophilicity. , 2011, Journal of medicinal chemistry.
[50] Z. Pan,et al. Synaptic Mechanism for Functional Synergism between δ- and μ-Opioid Receptors , 2010, The Journal of Neuroscience.
[51] M. Waldhoer,et al. Opioid-receptor-heteromer-specific trafficking and pharmacology. , 2010, Current opinion in pharmacology.
[52] X. Pu,et al. Chronic morphine administration induces over-expression of aldolase C with reduction of CREB phosphorylation in the mouse hippocampus. , 2009, European journal of pharmacology.
[53] Yuichi Sugiyama,et al. Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.
[54] Richard Morphy,et al. Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.
[55] S. Husbands,et al. Effects of Atypical κ-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.
[56] C. Bertucci,et al. Species-dependent stereoselective drug binding to albumin: a circular dichroism study. , 2008, Chirality.
[57] Xiao Chen,et al. Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment , 2007, Cell Research.
[58] Lawrence X. Yu,et al. Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay , 2007 .
[59] G. Trainor,et al. The importance of plasma protein binding in drug discovery , 2007, Expert opinion on drug discovery.
[60] W. Dewey,et al. PKC and PKA inhibitors reinstate morphine-induced behaviors in morphine tolerant mice. , 2006, Pharmacological research.
[61] L. Jia,et al. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[62] David J. Daniels,et al. A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .
[63] K. Rice,et al. Opioid Interactions in Rhesus Monkeys: Effects of δ + μ and δ + κ Agonists on Schedule-Controlled Responding and Thermal Nociception , 2003, Journal of Pharmacology and Experimental Therapeutics.
[64] N. Lee,et al. Opioid receptor interactions: local and nonlocal, symmetric and asymmetric, physical and functional. , 2003, Life sciences.
[65] B. Fermini,et al. The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.
[66] Michael J Banker,et al. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. , 2003, Journal of pharmaceutical sciences.
[67] P. Portoghese,et al. Identity of the putative δ1-opioid receptor as a δ–κ heteromer in the mouse spinal cord , 2003 .
[68] M. Narita,et al. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. , 2003, European journal of pharmacology.
[69] N. Mello,et al. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. , 2001, Bioorganic & medicinal chemistry letters.
[70] R. Hurley,et al. A cellular mechanism for the antinociceptive effect of a kappa opioid receptor agonist , 2001, Pain.
[71] J. Kamei,et al. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys. , 2001, Japanese journal of pharmacology.
[72] M. Narita,et al. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. , 2000, European journal of pharmacology.
[73] J. Kamei,et al. Characterization of the antinociceptive effects of TRK-820 in the rat. , 2000, European journal of pharmacology.
[74] M. Narita,et al. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist , 1999 .
[75] E. Weber,et al. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice. , 1998, Pharmacological research.
[76] D. Sawyer,et al. Kappa Antinociceptive Activity of Spiradoline in the Cold-Water Tail-Flick Assay in Rats , 1998, Pharmacology Biochemistry and Behavior.
[77] J. Levine,et al. κ- and δ-opioid agonists synergize to produce potent analgesia , 1990, Brain Research.
[78] J. W. Gates,et al. The Replacement of Phenolic Hydroxyl Groups by Hydrogen , 1966 .
[79] F. Carroll,et al. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats , 2017, Psychopharmacology.
[80] M. Kainoh,et al. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys. , 2016, Journal of pharmacological sciences.
[81] G. Koob,et al. Compulsive-Like Responding for Opioid Analgesics in Rats with Extended Access , 2015, Neuropsychopharmacology.